The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnimalcare Grp Regulatory News (ANCR)

Share Price Information for Animalcare Grp (ANCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 236.00
Bid: 232.00
Ask: 240.00
Change: 0.00 (0.00%)
Spread: 8.00 (3.448%)
Open: 236.00
High: 240.00
Low: 236.00
Prev. Close: 236.00
ANCR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cortacare receives positive opinion from CVMP

9 Jul 2018 07:00

RNS Number : 9706T
Animalcare Group PLC
09 July 2018
 

 

09 July 2018

 

Animalcare Group plc

 

("Animalcare", the "Company" or the "Group")

 

Cortacare recommended for European marketing approval by CVMP

 

- Launch in European markets expected in Q4 2018

- Expands Animalcare's dermatology portfolio

 

Animalcare Group plc (AIM:ANCR), the pan-European animal health business, today announces that it has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), recommending European marketing authorisation for its dermatology product Cortacare. Animalcare plans to launch Cortacare in Q4 2018 through its direct sales operations in seven European countries and international distribution network.

Cortacare is a wholly-owned product, developed by Animalcare as a cutaneous spray for the treatment of inflammatory and pruritic dermatitis in dogs. The product is a corticosteroid designed to be applied topically to reduce inflammation and itching, which complements Animalcare's existing dermatology portfolio. Cortacare accumulates in the dog's skin, allowing for high local activity whilst minimising side effects, and leading to an improvement of skin lesions associated with the condition.

Chris Cardon, CEO of Animalcare Group plc, commented:

"As part of the reprioritisation of our product development pipeline we identified 17 core development products. We are pleased to see the first of these receive a positive recommendation from the CVMP, which paves the way for the commercialisation of this wholly owned product across Europe and expands our existing dermatology portfolio. Product development remains a key area for us and we are focused on building value within our development pipeline. We look forward to announcing further success as the pipeline progresses."

Enquiries:

 

Animalcare Group plc

Chris Cardon, Chief Executive Officer

Tel: 01904 487 687

Chris Brewster, Chief Financial Officer

Panmure Gordon (UK) Ltd (Nominated Adviser & Broker)

Tel: 020 7886 2500

Corporate Finance

Freddy Crossley / Peter Steel

Corporate Broking

James Stearns

Consilium Strategic Communications

Tel: 020 3709 5700

Amber Fennell

animalcare@consilium-comms.com

Chris Welsh

Olivia Manser

 

About Animalcare Group plc

Animalcare is a pan-European sales, marketing and product development company focused on the veterinary and animal health sectors. The Company has operations across Europe with direct sales in seven countries (UK, Belgium, Netherlands, Spain, Portugal, Italy and Germany), and exports to approximately 40 markets worldwide through global partnerships. The Company sells over 300 products including pharmaceuaticals, vaccines and nutraceuticals . Animalcare has a diverse pipeline of products in development and a strong network of distribution and in-license partnerships. For more information, please visit: www.animalcaregroup.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFVLLBVDFZBBX
Date   Source Headline
12th Jul 202111:04 amRNSNotification of Major Holding
12th Jul 20217:00 amRNSExercise of options
9th Jul 20214:59 pmRNSNotification of Major Holding
9th Jul 20213:20 pmRNSNotification of Major Holding
8th Jul 20215:45 pmRNSResult of Secondary Placing
8th Jul 20214:41 pmRNSSecond Price Monitoring Extn
8th Jul 20214:35 pmRNSPrice Monitoring Extension
8th Jul 20212:06 pmRNSSecond Price Monitoring Extn
8th Jul 20212:00 pmRNSPrice Monitoring Extension
8th Jul 20211:00 pmRNSProposed Secondary Placing
1st Jul 20217:00 amRNSTotal Voting Rights
21st Jun 20217:00 amRNSExercise of options
17th Jun 202110:17 amRNSDirector/PDMR Notification
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20215:03 pmRNSResult of 2021 AGM
17th May 20217:00 amRNSAnnual Report 2020 and Notice of AGM
22nd Apr 20217:00 amRNSDaxocox approved by EU and UK authorities
30th Mar 20217:00 amRNSFull Year Results 2020
23rd Mar 20217:00 amRNSNotification of major holding
18th Feb 20214:36 pmRNSPrice Monitoring Extension
18th Feb 20213:43 pmRNSDaxocox receives positive opinion from CVMP in EU
8th Feb 20212:46 pmRNSNotification of major holding
1st Feb 20217:00 amRNSAppointment of Nominated Advisor and Joint Broker
21st Jan 20217:00 amRNSTrading Update and Notice of Full Year Results
18th Nov 20207:00 amRNSGrant of options
29th Sep 20207:00 amRNSInterim Results H1 2020
28th Sep 20207:00 amRNSAnimalcare and Kane Biotech to target biofilms
23rd Jul 20207:00 amRNSTrading Update and Notice of Results
30th Jun 20204:00 pmRNSResult of AGM 2020
9th Jun 20203:55 pmRNS2019 Annual Report and Notice of 2020 AGM
28th May 20207:00 amRNSFull year results 2019
18th May 202011:20 amRNSNotice of Full Year 2019 Results
25th Mar 20207:00 amRNSTrading update, revised date for full year results
23rd Jan 20207:00 amRNSTrading Update & Notice of Results
17th Jan 20208:55 amRNSHoldings in Company
24th Sep 20197:00 amRNSHalf Year Results
25th Jul 20197:00 amRNSDirectorate Change
23rd Jul 20197:00 amRNSTrading Update & Notice of Results
16th Jul 201911:37 amRNSNotification of major holdings
25th Jun 20191:40 pmRNSResult of AGM
19th Jun 20193:52 pmRNSBoard change
10th Jun 20192:55 pmRNSDirector/PDMR Shareholding
22nd May 20197:00 amRNSAnnual Report and Notice of Annual General Meeting
8th May 201910:35 amRNSDividend Declaration
30th Apr 20197:00 amRNS2018 Full Year Results
21st Jan 20197:00 amRNSTrading Update and Notice of Results
30th Oct 20187:50 amRNSAdditional Listing
1st Oct 201812:45 pmRNSAdditional Listing
25th Sep 20185:36 pmRNSDividend Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.